Novozymes A/S (NVZMY) Stock Price, News & Analysis

Company Overview

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Key Stats

• Today's Range: $60.80 to $64.72
• 50-Day Range: $55.34 to $63.16
• 52-Week Range: $52.96 to $72.50
• Volume: 8,120 shs
• Average Volume: 31,515 shs
• Market Capitalization: $29.58 billion
• P/E Ratio: 39.97
• Dividend Yield: 1.19%
• Price Target: N/A
• Consensus Rating: Buy

Novozymes A/S Stock Analysis - MarketRank™

Novozymes A/S scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Novozymes A/S.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 17.58%

Earnings Growth

Earnings for Novozymes A/S are expected to grow by 17.58% in the coming year, from $1.82 to $2.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novozymes A/S is 39.97, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novozymes A/S is 39.97, which means that it is trading at a less expensive P/E ratio than the Basic Materials sector average P/E ratio of about 74.64.

Price to Earnings Growth Ratio

Novozymes A/S has a PEG Ratio of 3.87. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novozymes A/S has a P/B Ratio of 14.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Novozymes A/S has been sold short.

Short Interest Ratio / Days to Cover

Novozymes A/S has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novozymes A/S has recently increased by 570.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novozymes A/S pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novozymes A/S does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novozymes A/S is 47.47%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 35.05% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Novozymes A/S has been sold short.

Short Interest Ratio / Days to Cover

Novozymes A/S has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novozymes A/S has recently increased by 570.59%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Novozymes A/S this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novozymes A/S insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.03% of the stock of Novozymes A/S is held by institutions.

NVZMY Stock Analysis - Frequently Asked Questions

How have NVZMY shares performed this year?

Novozymes A/S's stock was trading at $56.5399 at the start of the year. Since then, NVZMY stock has increased by 11.7% and is now trading at $63.16.
View the best growth stocks for 2025 here.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) issued its earnings results on Wednesday, January, 31st. The biotechnology company reported $0.36 earnings per share for the quarter, missing analysts' consensus estimates of $0.47 by $0.11. The biotechnology company had revenue of $664.46 million for the quarter.

Does Novozymes A/S have any subsidiaries?

The following companies are subsidiaries of Novozymes A/S: PrecisionBiotics Group Limited, OrganoBalance GmbH, Pacific Vet Group-USA, Allopartis, TJ Technologies, Iogen Bio-Products, Natural Industries, and others.

How do I buy shares of Novozymes A/S?

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 1/31/2024
• Record date for 4/23 Dividend: 4/07/2025
• Ex-Dividend for 4/23 Dividend: 4/07/2025
• Dividend Payable: 4/23/2025
• Today: 4/25/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Basic Materials
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NVZMY
• CIK: 1131345
• Web: www.novozymes.com
• Phone: (454) 446-0000
• Fax: 45-4446-9999
• Employees: 6,756
• Year Founded: 2000

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 39.97
• Forward P/E Ratio: 34.70
• P/E Growth: 3.87
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.60 billion
• Price / Sales: 11.39
• Cash Flow: $0.87 per share
• Price / Cash Flow: 72.83
• Book Value: $4.45 per share
• Price / Book: 14.19

Miscellaneous

• Outstanding Shares: 468,299,000
• Free Float: N/A
• Market Cap: $29.58 billion
• Optionable: Not Optionable
• Beta: 0.91